DOCSLIB.ORG

Mesothelioma Source: Globocan 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Mesothelioma Source: Globocan 2020 Number of new cases in 2020, both sexes, all ages Number of deaths in 2020, both sexes, all ages Breast 2 261 419 Lung 1 796 144 Lung 2 206 771 Colorectum 935 173 Colorectum 1 931 590 Liver 830 180 Prostate 1 414 259 Stomach 768 793 Stomach 1 089 103 Breast 684 996 Liver 905 677 Oesophagus 544 076 Cervix uteri 604 127 Pancreas 466 003 Oesophagus 604 100 Prostate 375 304 Thyroid 586 202 Cervix uteri 341 831 Bladder 573 278 Leukaemia 311 594 Non-Hodgkin lymphoma 544 352 Non-Hodgkin lymphoma 259 793 Pancreas 495 773 Brain, central nervous system 251 329 Leukaemia 474 519 Bladder 212 536 Kidney 431 288 Ovary 207 252 Corpus uteri 417 367 Kidney 179 368 Lip, oral cavity 377 713 Lip, oral cavity 177 757 Melanoma of skin 324 635 Multiple myeloma 117 077 Ovary 313 959 Larynx 99 840 Brain, central nervous system 308 102 Corpus uteri 97 370 Larynx 184 615 Gallbladder 84 695 Multiple myeloma 176 404 Nasopharynx 80 008 Nasopharynx 133 354 Melanoma of skin 57 043 Gallbladder 115 949 Oropharynx 48 143 Oropharynx 98 412 Thyroid 43 646 Hypopharynx 84 254 Hypopharynx 38 599 Hodgkin lymphoma 83 087 Mesothelioma 26 278 Testis 74 458 Hodgkin lymphoma 23 376 Salivary glands 53 583 Salivary glands 22 778 Vulva 45 240 Vulva 17 427 Penis 36 068 Kaposi sarcoma 15 086 Kaposi sarcoma 34 270 Penis 13 211 Mesothelioma 30 870 Testis 9 334 Vagina 17 908 Vagina 7 995 0 500 000 1 000 000 1 500 000 2 000 000 0 500 000 1 000 000 1 500 000 Cancer incidence and mortality statistics worldwide and by region Incidence Mortality Both sexes Males Females Both sexes Males Females Cum. risk Cum. risk Cum. risk Cum. risk Cum. risk Cum. risk New cases New cases New cases Deaths Deaths Deaths 0-74 (%) 0-74 (%) 0-74 (%) 0-74 (%) 0-74 (%) 0-74 (%) Eastern Africa 137 0.01 96 0.01 41 0.00 132 0.01 92 0.01 40 0.00 Middle Africa 57 0.01 44 0.01 13 0.00 56 0.01 43 0.01 13 0.00 Northern Africa 513 0.03 320 0.04 193 0.02 467 0.02 287 0.03 180 0.02 Southern Africa 296 0.07 203 0.12 93 0.03 270 0.07 181 0.13 89 0.03 Western Africa 116 0.01 102 0.02 14 0.00 113 0.01 99 0.02 14 0.00 Caribbean 31 0.01 25 0.01 6 0.00 28 0.01 24 0.01 4 0.00 Central America 389 0.03 254 0.04 135 0.02 351 0.02 232 0.04 119 0.01 South America 818 0.02 491 0.02 327 0.01 703 0.02 428 0.02 275 0.01 Northern America 4 119 0.05 3 083 0.08 1 036 0.03 3 119 0.04 2 388 0.05 731 0.02 Eastern Asia 5 815 0.02 3 863 0.03 1 952 0.02 4 918 0.02 3 341 0.03 1 577 0.01 South-Eastern Asia 782 0.01 438 0.01 344 0.01 687 0.01 393 0.01 294 0.01 South-Central Asia 1 972 0.01 1 041 0.01 931 0.01 1 772 0.01 920 0.01 852 0.01 Western Asia 1 166 0.06 677 0.07 489 0.05 947 0.05 587 0.06 360 0.04 Central and Eastern Europe 2 133 0.05 1 149 0.06 984 0.04 1 858 0.04 1 031 0.06 827 0.03 Western Europe 4 628 0.09 3 567 0.15 1 061 0.04 3 970 0.07 3 141 0.13 829 0.03 Southern Europe 2 941 0.09 2 159 0.14 782 0.04 2 596 0.07 1 912 0.11 684 0.03 Northern Europe 3 946 0.18 3 244 0.31 702 0.06 3 396 0.12 2 849 0.21 547 0.04 Australia and New Zealand 1 000 0.14 799 0.22 201 0.06 886 0.11 729 0.17 157 0.05 Melanesia 11 0.02 5 0.02 6 0.02 9 0.01 4 0.01 5 0.01 Polynesia 0 0 0 0 0 0 0 0 0 0 0 0 Micronesia 0 0 0 0 0 0 0 0 0 0 0 0 Low HDI 318 0.01 255 0.01 63 0.00 306 0.01 245 0.01 61 0.00 Medium HDI 2 395 0.01 1 218 0.01 1 177 0.01 2 151 0.01 1 086 0.01 1 065 0.01 High HDI 5 606 0.02 3 335 0.02 2 271 0.01 4 902 0.02 2 997 0.02 1 905 0.01 Very high HDI 22 542 0.07 16 743 0.12 5 799 0.04 18 910 0.06 14 344 0.09 4 566 0.03 World 30 870 0.03 21 560 0.05 9 310 0.02 26 278 0.03 18 681 0.04 7 597 0.02 Incidence, both sexes Mortality, both sexes 5-year prevalence, both sexes Africa Africa Africa (3.6%) (4%) (3.5%) LAC** LAC** LAC** (4%) Europe (4.1%) Europe (4.2%) Europe (44.2%) (45%) (43.6%) N.America* N.America* N.America* (13.3%) (11.9%) (13.1%) Asia Asia Asia (31.5%) (31.7%) (32.6%) Population Number Population Number Population Number Europe 13 648 Europe 11 820 Europe 16 135 Asia 9 735 Asia 8 324 Asia 12 090 *Northern America 4 119 *Northern America 3 119 *Northern America 4 850 **Latin America and the Caribbean 1 238 **Latin America and the Caribbean 1 082 **Latin America and the Caribbean 1 558 Africa 1 119 Africa 1 038 Africa 1 281 Oceania 1 011 Oceania 895 Oceania 1 133 Total 30 870 Total 26 278 Total 37 047 The Global Cancer Observatory - All Rights Reserved, December, 2020. Page 1 Age standardized (World) incidence rates, mesothelioma, males, all ages ≥ 0.79 0.27–0.79 0.13–0.27 0.07–0.13 Not applicable 0.0–0.07 No data Age standardized (World) incidence rates, mesothelioma, females, all ages ≥ 0.24 0.12–0.24 0.04–0.12 0.0–0.04 Not applicable No data Data source: GLOBOCAN 2020 Graph production: IARC (https://gco.iarc.fr/today) World Health Organization © International Agency for Research on Cancer 2020 Age standardized (World) incidence rates, mesothelioma, by sex Age standardized (World) incidence and mortality rates, mesothelioma Males Females Incidence Mortality Northern Europe 2.5 0.46 Northern Europe 1.4 1.1 Australia and New Zealand 2.2 0.57 Australia and New Zealand 1.3 1.1 Western Europe 1.3 0.35 Western Europe 0.79 0.65 Southern Europe 1.1 0.36 Southern Europe 0.70 0.58 Southern Africa 0.95 0.29 Southern Africa 0.55 0.51 Northern America 0.75 0.25 Western Asia 0.48 0.39 Western Asia 0.58 0.39 Northern America 0.47 0.33 Central and Eastern Europe 0.53 0.31 Central and Eastern Europe 0.41 0.32 World 0.46 0.17 World 0.30 0.25 Northern Africa 0.32 0.17 Northern Africa 0.24 0.22 Central America 0.31 0.14 Central America 0.21 0.19 Eastern Asia 0.28 0.14 Eastern Asia 0.20 0.16 South America 0.20 0.11 South America 0.15 0.13 Melanesia 0.16 0.14 Melanesia 0.14 0.12 South-Eastern Asia 0.13 0.09 South-Eastern Asia 0.11 0.09 Middle Africa 0.11 0.03 South-Central Asia 0.10 0.09 Western Africa 0.11 0.01 Middle Africa 0.07 0.06 South-Central Asia 0.11 0.10 Eastern Africa 0.06 0.06 Eastern Africa 0.09 0.03 Western Africa 0.06 0.06 Caribbean 0.08 0.02 Caribbean 0.05 0.04 Polynesia Polynesia Micronesia Micronesia 6.0 5.0 4.0 3.0 2.0 1.0 0 1.0 2.0 3.0 4.0 5.0 6.0 3.0 2.5 2.0 1.5 1.0 0.5 0 0.5 1.0 1.5 2.0 2.5 3.0 ASR (World) per 100 000 ASR (World) per 100 000 The Global Cancer Observatory - All Rights Reserved, December, 2020. Page 2.
Recommended publications
  • Follicular Lymphoma

    Follicular Lymphoma

    Follicular Lymphoma What is follicular lymphoma? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines FOLLICULAR LYMPHOMA: A GUIDE FOR PATIENTS PATIENT INFORMATION BASED ON ESMO CLINICAL PRACTICE GUIDELINES This guide for patients has been prepared by the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of follicular lymphoma and appreciate the best treatment choices available according to the subtype of follicular lymphoma. We recommend that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease. The medical information described in this document is based on the clinical practice guidelines of the European Society for Medical Oncology (ESMO) for the management of newly diagnosed and relapsed follicular lymphoma. This guide for patients has been produced in collaboration with ESMO and is disseminated with the permission of ESMO. It has been written by a medical doctor and reviewed by two oncologists from ESMO including the lead author of the clinical practice guidelines for professionals, as well as two oncology nurses from the European Oncology Nursing Society (EONS). It has also been reviewed by patient representatives from ESMO’s Cancer Patient Working Group. More information about the Anticancer Fund: www.anticancerfund.org More information about the European Society for Medical Oncology: www.esmo.org For words marked with an asterisk, a definition is provided at the end of the document. Follicular Lymphoma: a guide for patients - Information based on ESMO Clinical Practice Guidelines – v.2014.1 Page 1 This document is provided by the Anticancer Fund with the permission of ESMO.
  • Risk Factors for Malignant Mesothelioma

    Risk Factors for Malignant Mesothelioma

    cancer.org | 1.800.227.2345 Malignant Mesothelioma Causes, Risk Factors, and Prevention Risk Factors A risk factor is anything that affects your chance of getting a disease such as cancer. Learn more about the risk factors for malignant mesothelioma. ● Risk Factors for Malignant Mesothelioma ● What Causes Malignant Mesothelioma? Prevention There's no way to completely prevent mesothelioma. But there are things you can do that might lower your risk. Learn more. ● Can Malignant Mesothelioma Be Prevented? Risk Factors for Malignant Mesothelioma A risk factor is anything that increases your chance of getting a disease such as cancer. Different cancers have different risk factors. Some risk factors, like smoking, can be changed. Others, like a person’s age or family history, can’t be changed. But having a 1 ____________________________________________________________________________________American Cancer Society cancer.org | 1.800.227.2345 known risk factor, or even many, does not mean that you will get the disease. And some people who get the disease may have few or no known risk factors. Researchers have found some factors that increase a person’s risk of mesothelioma. Asbestos The main risk factor for pleural mesothelioma is exposure to asbestos. In fact, most cases of pleural mesothelioma have been linked to high levels of asbestos exposure, usually in the workplace. Asbestos is a group of minerals that occur naturally as bundles of tiny fibers. These fibers are found in soil and rocks in many parts of the world. When asbestos fibers in the air are inhaled, they can get into the lungs. Fibers that stay in the lungs can travel to the ends of the small airways and enter the pleural lining of the lung and chest wall.
  • Non-Hodgkin's Lymphoma Questions and Answers

    Non-Hodgkin's Lymphoma Questions and Answers

    Non-Hodgkin's Lymphoma Questions and Answers What is Non-Hodgkin's Lymphoma? Non-Hodgkin’s lymphoma (NHL) is a cancer of the lymphocytes, a type of white blood cell. When lymphocytes become cancerous (malignant), they multiply and become tumors. Lymphocytes are normally found in the blood stream and lymph nodes. Lymph nodes are found throughout the body and are identified by their location. They are a part of the body’s immune system, which includes the lymphatic system, spleen and lymphocytes. Some lymph nodes can be found just by feeling them in the neck, groin or under the arms. Some cannot be felt, but they can be seen on X-rays. NHL is the fifth most common cancer in the United States. Men are at slightly higher risk than women. It is more common in adults than children. The average age at diagnosis is 45 to 55 years. The cause of NHL remains unknown. What Are the Types and Symptoms of Non-Hodgkin’s Lymphoma? There are more than 30 different types of NHL. The specific types of NHL are associated with different symptoms. Low-grade or indolent NHL is usually associated with painless swelling of lymph nodes (usually in the neck or over the collarbone), but patients are otherwise healthy. The swelling may go away for a while, but then return. If the low-grade NHL has spread outside of the lymph nodes, such as to the stomach, there may be discomfort in the affected area. Low-grade lymphomas grow slowly. Examples of low-grade NHLs include: Marginal zone lymphomas.
  • MINI-REVIEW Large Cell Lymphoma Complicating Persistent Polyclonal B

    MINI-REVIEW Large Cell Lymphoma Complicating Persistent Polyclonal B

    Leukemia (1998) 12, 1026–1030 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 http://www.stockton-press.co.uk/leu MINI-REVIEW Large cell lymphoma complicating persistent polyclonal B cell lymphocytosis J Roy1, C Ryckman1, V Bernier2, R Whittom3 and R Delage1 1Division of Hematology, 2Department of Pathology, Saint Sacrement Hospital, 3Division of Hematology, CHUQ, Saint Franc¸ois d’Assise Hospital, Laval University, Quebec City, Canada Persistent polyclonal B cell lymphocytosis (PPBL) is a rare immunoglobulin (Ig) M with a polyclonal pattern on protein lymphoproliferative disorder of unclear natural history and its electropheresis. Flow cytometry cell analysis displays the pres- potential for B cell malignancy remains unknown. We describe the case of a 39-year-old female who presented with stage IV- ence of the CD19 antigen and surface IgM with a normal B large cell lymphoma 19 years after an initial diagnosis of kappa/lambda ratio. In contrast to CLL, CD5 is absent. There PPBL; her disease was rapidly fatal despite intensive chemo- is an association between HLA-DR 7 and PPBL in more than therapy and blood stem cell transplantation. Because we had two-thirds of the patients but the reason for such an associ- recently identified multiple bcl-2/lg gene rearrangements in ation remains unclear.3,6 There has been one report of PPBL blood mononuclear cells of patients with PPBL, we sought evi- occurring in identical female twins.7 No other obvious genetic dence of this oncogene in this particular patient: bcl-2/lg gene rearrangements were found in blood mononuclear cells but not predisposition or familial inheritance has yet been described in lymphoma cells.
  • Solitary Fibrous Tumor of the Pleura: Histology, CT Scan Images and Review of Literature Over the Last Twenty Years

    Solitary Fibrous Tumor of the Pleura: Histology, CT Scan Images and Review of Literature Over the Last Twenty Years

    DOI: 10.26717/BJSTR.2017.01.000150 Flavio Colaut. ISSN: 2574-1241 Biomed J Sci & Tech Res Case Report Open Access Solitary Fibrous Tumor of the Pleura: Histology, CT Scan Images and Review of Literature over the Last Twenty Years Giulia Bora1, Flavio Colaut2*, Gianni Segato3, Luisa Delsedime4 and Alberto Oliaro1 1Department of Thoracic Surgery, University of Turin, Italy 2Department of General Surgery and Thoracic, City Hospital , Montebelluna, (Treviso), Italy 3Department of General Surgery, S. Bortolo City Hospital, Vicenza, Italy 4Department of Pathology, University of Turin, Italy Received: June 14, 2017; Published: June 26, 2017 *Corresponding author: Flavio Colaut, Department of General Surgery, City Hospital Montebelluna, Thoracic City Hospital, via Montegrappa 1, 31044 Montebelluna (Treviso), Italy, Tel: ; Fax: 0499367643; Email: Introduction Literature up to 800 cases [1-3] have been reported, and these in case of recurrence [10,16,17]. In less than 5% of patients with Solitary fibrous tumor of the pleura is a rare neoplasm. In numbers show its rarity, despite of mesotheliomas, the most pleural SFPTs an increase of insulin-like factor II type occur and this causes refractory to therapy hypoglycaemia (Doege-Potter syndrome) similar in both sexes and there no differences in both benign and [10,18,19]. The incidence of Doege-Potter syndrome in SFPT is tumors represented. Males and females are equal distributed asbestos, tobacco or others environmental agents, were found for and the same is true for age. No correlation with exposure to malignantSome patients forms. may also present gynecomastia or galactorrhoea its development. Solitary fibrous tumor of the pleura occurs as localized neoplasms of the pleura and was initially classified as microscope and immunohistochemistry, has been possible [1].
  • Global Mesothelioma Deaths Reported

    Global Mesothelioma Deaths Reported

    ResearchResearch Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008 Vanya Delgermaa,a Ken Takahashi,a Eun-Kee Park,a Giang Vinh Le,a Toshiyuki Haraa & Tom Sorahanb Objective To carry out a descriptive analysis of mesothelioma deaths reported worldwide between 1994 and 2008. Methods We extracted data on mesothelioma deaths reported to the World Health Organization mortality database since 1994, when the disease was first recorded. We also sought information from other English-language sources. Crude and age-adjusted mortality rates were calculated and mortality trends were assessed from the annual percentage change in the age-adjusted mortality rate. Findings In total, 92 253 mesothelioma deaths were reported by 83 countries. Crude and age-adjusted mortality rates were 6.2 and 4.9 per million population, respectively. The age-adjusted mortality rate increased by 5.37% per year and consequently more than doubled during the study period. The mean age at death was 70 years and the male-to-female ratio was 3.6:1. The disease distribution by anatomical site was: pleura, 41.3%; peritoneum, 4.5%; pericardium, 0.3%; and unspecified sites, 43.1%. The geographical distribution of deaths was skewed towards high-income countries: the United States of America reported the highest number, while over 50% of all deaths occurred in Europe. In contrast, less than 12% occurred in middle- and low-income countries. The overall trend in the age- adjusted mortality rate was increasing in Europe and Japan but decreasing in the United States. Conclusion The number of mesothelioma deaths reported and the number of countries reporting deaths increased during the study period, probably due to better disease recognition and an increase in incidence.
  • Understanding Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

    Understanding Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

    Understanding Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are forms of non-Hodgkin lymphoma (NHL) that arise from B lymphocytes. CLL and SLL are essentially the same disease, with the only difference being the location where the cancer primarily occurs. When most of the cancer cells are located in the bloodstream and the bone marrow, the disease is referred to as CLL, although the lymph nodes and spleen are often involved. When the cancer cells are located mostly in the lymph nodes and are less frequent in the blood, the disease is called SLL. Many patients with CLL/SLL do not have any obvious symptoms of the disease. Their doctors might detect the disease during routine blood tests and/or a physical examination. For others, the disease is detected when symptoms occur and the patient goes to the doctor because he or she is worried, uncomfortable, or does not feel well. CLL/SLL may cause different symptoms depending on the location of the tumor in the body, including fatigue (extreme tiredness), shortness of breath, anemia (low red blood cell count), bruising easily, night sweats, weight loss, frequent infections. Other symptoms can include a swollen abdomen and feeling full even after eating only a small amount. However, many patients with CLL/SLL will live for years without symptoms. TREATMENT OPTIONS • Chlorambucil (Leukeran) and obinutuzumab (Gazyva) • Venetoclax (Venclexta) and obinutuzumab (Gazyva) Treatment is based on the severity of associated symptoms Occasionally patients might also be treated with chemotherapy, as well as the rate of cancer growth.
  • NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’S Lymphomas Version 2.2015

    NCCN Guidelines Index NHL Table of Contents Discussion NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines® ) Non-Hodgkin’s Lymphomas Version 2.2015 NCCN.org Continue Version 2.2015, 03/03/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN® . Peripheral T-Cell Lymphomas NCCN Guidelines Version 2.2015 NCCN Guidelines Index NHL Table of Contents Peripheral T-Cell Lymphomas Discussion DIAGNOSIS SUBTYPES ESSENTIAL: · Review of all slides with at least one paraffin block representative of the tumor should be done by a hematopathologist with expertise in the diagnosis of PTCL. Rebiopsy if consult material is nondiagnostic. · An FNA alone is not sufficient for the initial diagnosis of peripheral T-cell lymphoma. Subtypes included: · Adequate immunophenotyping to establish diagnosisa,b · Peripheral T-cell lymphoma (PTCL), NOS > IHC panel: CD20, CD3, CD10, BCL6, Ki-67, CD5, CD30, CD2, · Angioimmunoblastic T-cell lymphoma (AITL)d See Workup CD4, CD8, CD7, CD56, CD57 CD21, CD23, EBER-ISH, ALK · Anaplastic large cell lymphoma (ALCL), ALK positive (TCEL-2) or · ALCL, ALK negative > Cell surface marker analysis by flow cytometry: · Enteropathy-associated T-cell lymphoma (EATL) kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20, CD30, CD4, CD8, CD7, CD2; TCRαβ; TCRγ Subtypesnot included: · Primary cutaneous ALCL USEFUL UNDER CERTAIN CIRCUMSTANCES: · All other T-cell lymphomas · Molecular analysis to detect: antigen receptor gene rearrangements; t(2;5) and variants · Additional immunohistochemical studies to establish Extranodal NK/T-cell lymphoma, nasal type (See NKTL-1) lymphoma subtype:βγ F1, TCR-C M1, CD279/PD1, CXCL-13 · Cytogenetics to establish clonality · Assessment of HTLV-1c serology in at-risk populations.
  • Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

    Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma

    cancers Review Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma Fraser Brims 1,2,3 1 Curtin Medical School, Curtin University, Perth, WA 6845, Australia; [email protected] 2 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia 3 National Centre for Asbestos Related Diseases, Institute for Respiratory Health, Perth, WA 6009, Australia Simple Summary: Mesothelioma is a cancer of the lining of the lungs caused by breathing in asbestos fibres. Asbestos was widely used in industry in the last century in most developed countries and is still present in many older buildings to this day. There is no known safe level of asbestos exposure. Symptoms of mesothelioma can include worsening breathlessness, chest pain and loss of weight. There is no cure, and the treatment of mesothelioma is limited, although there have been some recent improvements in therapy. Survival is very variable although most people live for around one year after diagnosis. Efforts to improve and maintain the quality of life for patients with mesothelioma remain a priority. Abstract: Mesothelioma is a cancer predominantly of the pleural cavity. There is a clear association of exposure to asbestos with a dose dependent risk of mesothelioma. The incidence of mesothelioma in different countries reflect the historical patterns of commercial asbestos utilisation in the last century and predominant occupational exposures mean that mesothelioma is mostly seen in males. Modern imaging techniques and advances in immunohistochemical staining have contributed to an improved diagnosis of mesothelioma. There have also been recent advances in immune checkpoint inhibition, however, mesothelioma remains very challenging to manage, especially Citation: Brims, F.
  • Chrysotile Asbestos As a Cause of Mesothelioma: Application of the Hill Causation Model

    Chrysotile Asbestos As a Cause of Mesothelioma: Application of the Hill Causation Model

    Commentary Chrysotile Asbestos as a Cause of Mesothelioma: Application of the Hill Causation Model RICHARD A. LEMEN, PHD Chrysotile comprises over 95% of the asbestos used this method, researchers are asked to evaluate nine today. Some have contended that the majority of areas of consideration: strength of association, tempo- asbestos-related diseases have resulted from exposures rality, biologic gradient, consistency, specificity, bio- to the amphiboles. In fact, chrysotile is being touted as logic plausibility, coherence, experimental evidence, the form of asbestos which can be used safely. Causa- and analogy. None of these considerations, in and of tion is a controversial issue for the epidemiologist. How itself, is determinative for establishing a causal rela- much proof is needed before causation can be estab- tionship. As Hill himself noted, “[n]one of my nine lished? This paper examines one proposed model for establishing causation as presented by Sir Austin Brad- view points can bring indisputable evidence for or ford Hill in 1965. Many policymakers have relied upon against the cause and effect hypothesis, and none can this model in forming public health policy as well as be required as a sine qua non.” In the same vein, it is deciding litigation issues. Chrysotile asbestos meets not necessary for all nine considerations to be met Hill’s nine proposed criteria, establishing chrysotile before causation is established. Instead, Hill empha- asbestos as a cause of mesothelioma. Key words: sized that the responsibility for making causal judg- asbestos; chrysotile; amphiboles; causation; mesothe- ments rested with a scientific evaluation of the totality lioma; Hill model. of the data.
  • Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Lymphoma (SLL)

    Chronic Lymphocytic Leukaemia (CLL) and Small Lymphocytic Lymphoma (SLL)

    Helpline (freephone) 0808 808 5555 [email protected] www.lymphoma-action.org.uk Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) This information is about chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). CLL and SLL are different forms of the same illness. They are often grouped together as a type of slow-growing (low-grade or indolent) non-Hodgkin lymphoma. On this page What is CLL/SLL? Who gets CLL? Symptoms of CLL Diagnosis and staging Outlook Treatment Follow-up Relapsed or refractory CLL Research and targeted treatments We have separate information about the topics in bold font. Please get in touch if you’d like to request copies or if you would like further information about any aspect of lymphoma. Phone 0808 808 5555 or email [email protected]. Page 1 of 13 © Lymphoma Action What is CLL/SLL? Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are slow-growing types of blood cancer. They develop when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). CLL and SLL are different forms of the same illness. They develop when B cells that don’t work properly build up in your body. • In CLL, the abnormal B cells build up in your blood and bone marrow. This is why it’s called ‘leukaemia’ – after ‘leucocytes’: the medical name for white blood cells.
  • Non-Hodgkin Lymphoma

    Non-Hodgkin Lymphoma

    Non-Hodgkin Lymphoma Rick, non-Hodgkin lymphoma survivor This publication was supported in part by grants from Revised 2013 A Message From John Walter President and CEO of The Leukemia & Lymphoma Society The Leukemia & Lymphoma Society (LLS) believes we are living at an extraordinary moment. LLS is committed to bringing you the most up-to-date blood cancer information. We know how important it is for you to have an accurate understanding of your diagnosis, treatment and support options. An important part of our mission is bringing you the latest information about advances in treatment for non-Hodgkin lymphoma, so you can work with your healthcare team to determine the best options for the best outcomes. Our vision is that one day the great majority of people who have been diagnosed with non-Hodgkin lymphoma will be cured or will be able to manage their disease with a good quality of life. We hope that the information in this publication will help you along your journey. LLS is the world’s largest voluntary health organization dedicated to funding blood cancer research, education and patient services. Since 1954, LLS has been a driving force behind almost every treatment breakthrough for patients with blood cancers, and we have awarded almost $1 billion to fund blood cancer research. Our commitment to pioneering science has contributed to an unprecedented rise in survival rates for people with many different blood cancers. Until there is a cure, LLS will continue to invest in research, patient support programs and services that improve the quality of life for patients and families.